BioFire Diagnostics secures $25M from Athyrium Opportunities Fund

Wednesday, September 19, 2012 10:38 AM

BioFire Diagnostics, a clinical diagnostics company based in Salt Lake City, Utah, has completed a $25 million financing with Athyrium Opportunities Fund, a New York-based fund focusing on investment opportunities in the global healthcare sector

The proceeds from the financing will be used to accelerate the commercialization of the company's FilmArray diagnostic platform. Proceeds will also be used to further develop additional panels beyond the FDA-cleared, CE IVD marked, FilmArray Respiratory Panel (RP), which simultaneously tests 17 viral targets and three bacterial targets in approximately one hour. These additional panels include a blood culture ID panel (currently in clinical trials), a gastrointestinal panel and a meningitis panel.

"We are excited to partner with Athyrium during this transformative stage of the Company's life,” said Kirk Ririe, CEO of BioFire. “This investment strengthens our already solid capital position and the company's ability to further penetrate the molecular diagnostics market. The FilmArray Respiratory Panel is just the first of many exciting panels which will drive the utility of the FilmArray platform for the medical community in the coming years."

Richard Pines, a principal of Athyrium, added, "Athyrium believes that BioFire is poised for significant future growth as hospitals continue to de-centralize their molecular diagnostic workflows and increasingly demand access to multiplex systems that can handle their testing throughput. The company's current RP panel and robust pipeline of future panels will position BioFire as a leader in clinical diagnostics arena."

Share:          
CWWeekly

June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs